A NEW ANTITUMOR ANTIBIOTIC, FR900840: III. ANTITUMOR ACTIVITY AGAINST EXPERIMENTAL TUMORS

FR900840 ((2S)-2-amino-2-carboxyethyl (3R)-2-diazo-3-hydroxybutyrate), a new antibiotic with antitumor activity was isolated from the fermentation broth of Streptomyces sp. No. 8727. Its antitumor activity was examined in three mouse tumor systems and ten human tumor systems. FR900840 had no clear e...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antibiotics 1989/04/25, Vol.42(4), pp.553-557
Main Authors: NISHIMURA, MAKOTO, NAKADA, HIROHISA, KAWAMURA, IKUO, MIZOTA, TAMOTSU, SHIMOMURA, KYOICHI, NAKAHARA, KUNIO, GOTO, TOSHIO, YAMAGUCHI, ISAMU, OKUHARA, MASAKUNI
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Animals
Antibiotics, Antineoplastic - therapeutic use
Antibiotics, microbial producers, chemotherapic agents, antiseptics, disinfecting agents
Applied microbiology
Biological and medical sciences
Carcinoma, Small Cell - drug therapy
Carcinoma, Squamous Cell - drug therapy
Chemotherapic agents
Female
Fundamental and applied biological sciences. Psychology
Humans
Hydroxybutyrates - therapeutic use
Lung Neoplasms - drug therapy
Male
Mammary Neoplasms, Experimental - drug therapy
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Inbred DBA
Mice, Nude
Microbiology
Neoplasms, Experimental - drug therapy
Serine - analogs & derivatives
Serine - therapeutic use
Stomach Neoplasms - drug therapy
Tumor Cells, Cultured
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:FR900840 ((2S)-2-amino-2-carboxyethyl (3R)-2-diazo-3-hydroxybutyrate), a new antibiotic with antitumor activity was isolated from the fermentation broth of Streptomyces sp. No. 8727. Its antitumor activity was examined in three mouse tumor systems and ten human tumor systems. FR900840 had no clear effect on mouse ascitic tumors, P388 and L1210, and the B16 melanoma line, but had prominent antitumor effects on several human solid tumors. Its antitumor activity against A549 human lung adenocarcinoma was stronger than those of vinblastine, doxorubicin and cisplatin. These results suggest that FR900840 may become a useful prototype antitumor drug.
ISSN:0021-8820
1881-1469
DOI:10.7164/antibiotics.42.553